Sprint Bioscience Competitors and Similar CompaniesClear all

Sprint Bioscience's competitors and similar companies include Chugai Pharmaceutical, Epizyme, Janssen and Loxo Oncology.

	Sprint Bioscience Sprint Bioscience is a pharmaceutical company focused on developing drugs to fight cancer.	Chugai Pharmaceutical Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.	Janssen Janssen is a company providing prescription pharmaceutical products.	Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
Founding Date	Founding Date 2009	Founding Date 1925	Founding Date 2007	Founding Date 1953	Founding Date 2013
Type	Type Public	Type Public	Type Public	Type Subsidiary	Type Subsidiary
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma
Locations	Locations Huddinge, SE HQ	Locations Chuo City, JP HQ Guangzhou Shi, CN Taizhou, CN Puteaux, FR Frankfurt Am Main, DE Singapore, SG see more	Locations Cambridge, US HQ	Locations Raritan, US HQ Vienna, AT Prague, CZ Espoo, FI Budapest, HU Oslo, NO Belgrade, RS see more	Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US
Employees	Employees 38	Employees 7,778	Employees 20364% increase	Employees 17,3684% decrease	Employees 65610% decrease
Valuation ($)	Valuation ($) 13.8 m	Valuation ($) 78.7 b	Valuation ($) 250.8 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) kr167.2m (FY, 2025)	Revenue (est.) ¥1.3t (FY, 2025)	Revenue (est.) $37.4m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods kr13.1m (FY, 2025)	Cost of goods ¥363.7b (FY, 2025)	Cost of goods $10.5m (FY, 2021)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit kr154.3m (FY, 2025)	Gross profit ¥903.5b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income kr91.7m (FY, 2025)	Net income ¥434b (FY, 2025)	Net income ($251.1m) (FY, 2021)	Net income N/A	Net income ($148.9m) (FY, 2017)
Funding
Total funding raised	Total funding raised $ 5.4m	Total funding raised N/A	Total funding raised $ 51.5m	Total funding raised N/A	Total funding raised $ 57m